News

The deal will help Aptuit to provide its customers in the biotechnology and pharmaceutical sectors with a suite of early development services and competencies designed to accelerate and

The goal of the study is to more fully define the safety and efficacy of the Lilly/Alkermes inhaled insulin system in patients with diabetes. The phase III programme

This clinical trial, the first of four phase II studies planned for OGX-011 in 2005, is designed to assess the safety and efficacy of the drug in prostate

In the main study, involving 716 patients with wet age-related macular degeneration (AMD), Lucentis was shown not only to stop the progress of the disease, but to actually

Under the terms of the transaction, Sosei will pay the $187.4 million with an upfront payment of $20.7 million in cash, and issue 35,630 shares for the rest.

Orphan drug status is granted by the FDA in order to encourage the development of treatments for rare diseases and disorders. It means that Chemokine Therapeutics will be

The drug is already indicated for the treatment of influenza in children aged one year and above, but not yet for use as a preventative in this age

Development will resume pending discussion of plans and protocols with the FDA, with a mid phase clinical trial expected to begin in the fourth quarter of 2005. The

As a subcontractor under Harvard Medical School’s award, Avant Immunotherapeutics will receive approximately $374,000 of this funding over a twelve-month period. The project will use Avant’s VitriLife technology